Evidence map›Paper›PMID 36569861›Full record

ReviewFrontiers in immunology2022

Stepwise acquisition of unique epigenetic signatures during differentiation of tissue Treg cells.

Kathrin L Braband, Tamara Kaufmann, Stefan Floess, Mangge Zou, Jochen Huehn, Michael Delacher

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kathrin L BrabandInstitute for Immunology, University Medical Center Mainz, Mainz, Germany.
Tamara KaufmannInstitute for Immunology, University Medical Center Mainz, Mainz, Germany.
Stefan FloessDepartment of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Mangge ZouDepartment of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Jochen HuehnDepartment of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Michael DelacherInstitute for Immunology, University Medical Center Mainz, Mainz, Germany.
Helmholtz Centre for Infection Research · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T cells in non-lymphoid tissues are not only critical for maintaining self-tolerance, but are also important for promoting organ homeostasis and tissue repair. It is proposed that the generation of tissue Treg cells is a stepwise, multi-site process, accompanied by extensive epigenome remodeling, finally leading to the acquisition of unique tissue-specific epigenetic signatures. This process is initiated in the thymus, where Treg cells acquire core phenotypic and functional properties, followed by a priming step in secondary lymphoid organs that permits Treg cells to exit the lymphoid organs and seed into non-lymphoid tissues. There, a final specialization process takes place in response to unique microenvironmental cues in the respective tissue. In this review, we will summarize recent findings on this multi-site tissue Treg cell differentiation and highlight the importance of epigenetic remodeling during these stepwise events.

Indexed as

Immune ToleranceT-Lymphocytes, RegulatoryCell DifferentiationEpigenesis, GeneticSelf ToleranceepigeneticshomeostasismethylationtissueTreg

Identifiers

PMID36569861
PMCPMC9772052
OpenAlexW4311848681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.